Evidence map›Paper›PMID 41258324›Full record

ArticlePharmacological reports : PR2026

Novel LC-MS/MS method for measuring methotrexate in high-dose therapy: a comparative study with commercial EMIT and EIA immunoassays.

Agnieszka Czajkowska, Aleksandra Mikulska, Martyna Poniewierska, Agnieszka Suchan, Maciej Sierakowski, Tomasz Pawiński, Arkadiusz Kocur

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacological reports : PR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Agnieszka Czajkowska *Therapeutic Drug Monitoring, Clinical Pharmacokinetics and Toxicology Laboratory Unit, Department of Clinical Biochemistry, The Children's Memorial Health Institute, Warszawa, 04-730, Poland.
Aleksandra Mikulska *Department of Drug Chemistry, Pharmaceutical and Biomedical Analysis, Faculty of Pharmacy, Medical University of Warsaw, Warszawa, 02-097, Poland.
Martyna PoniewierskaAltium International Sp. z o. o, Warszawa, 02-785, Poland.
Agnieszka SuchanAltium International Sp. z o. o, Warszawa, 02-785, Poland.
Maciej SierakowskiInstitute of Biological Sciences, Cardinal Stefan Wyszyński University, 1/3 Kazimierza Wóycickiego St, Warszawa, 01-938, Poland.
Tomasz PawińskiDepartment of Drug Chemistry, Pharmaceutical and Biomedical Analysis, Faculty of Pharmacy, Medical University of Warsaw, Warszawa, 02-097, Poland.
Arkadiusz KocurDepartment of Drug Chemistry, Pharmaceutical and Biomedical Analysis, Faculty of Pharmacy, Medical University of Warsaw, Warszawa, 02-097, Poland. arkadiusz.kocur@wum.edu.pl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMethotrexate (MTX) is a widely used chemotherapeutic agent in pediatric oncology, where high-dose protocols (HDMTX; ≥500 mg/m

methodsThe presented study aimed to compare the analytical performance of two immunoassays-enzyme-multiplied immunoassay technique (EMIT) and enzyme immunoassay (EIA)-against a newly developed and validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method.

resultsThe LC-MS/MS assay demonstrated excellent linearity, sensitivity (LLOQ = 0.01 µmol/L), and precision, meeting ICH M10 regulatory guidelines. Clinical samples from pediatric patients receiving HDMTX were analyzed using all three methods. Results showed strong correlations (r > 0.93) between methods; however, immunoassays exhibited biases related to cross-reactivity with MTX metabolites such as DAMPA (2,4-diamino-N

conclusionsWhile immunoassays remain practical for routine monitoring due to their accessibility and speed, LC-MS/MS provides superior accuracy and should be the method of choice in critical clinical situations. These findings underscore the importance of selecting the appropriate assay to optimize HDMTX therapy and ensure patient safety.

Indexed as

Antimetabolites, AntineoplasticDrug MonitoringEnzyme Multiplied Immunoassay TechniqueMethotrexateTandem Mass SpectrometryChildChromatography, LiquidHumansImmunoenzyme TechniquesLiquid Chromatography-Mass SpectrometryReproducibility of ResultsAntimetabolites, AntineoplasticMethotrexateEIAEMITLC-MS/MSMethotrexatePediatric oncologyTherapeutic drug monitoring

Identifiers

PMID41258324
PMCPMC12795967

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.